Do follow-up tests actually help detect recurrent disease?
Nelson
N J
NJ
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000378:metabolism; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism / Q000473:pathology* / Q000517:prevention & control* / Q000523:psychology; D020847:Estrogen Receptor Modulators / Q000009:adverse effects; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary; D008403:Mass Screening / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000009:adverse effects; D013997:Time Factors; D014481:United States / Q000453:epidemiology; D014594:Uterine Neoplasms / Q000139:chemically induced / Q000517:prevention & control*
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen